caa a22 4500 469073489 CHVBK 20180323132928.0 cr unu---uuuuu 170328e19920101xx s 000 0 eng 10.1007/BF01741053 doi (NATIONALLICENCE)springer-10.1007/BF01741053 Induction of antitumor activities in spleen cells from mice and rats activated with lipopolysaccharide immobilized on beads [Elektronische Daten] [Hajime Abe, Tohru Tani, Junsuke Shibata, Masashi Kodama] Summary: Lipopolysaccharides (LPS) were coupled to polystyrene beads in order to apply the LPS without toxicity. The antitumor activity of the LPS-immobilizing beads was studied in experiments in vitro and in vivo. In vitro studies showed that spleen cells from C3H/HeN mice stimulated by beads immobilizing LPS fromEscherichia coli produced cytolytic activity as strong as that of lymphokine-activated killer (LAK) cells. Spleen cells from Sprague-Dawley rats stimulated by beads immobilizing LPS fromSalmonella minnesota produced cytolytic activity stronger than that of LAK cells. However, spleen cells stimulated by beads immobilizing each component of the LPS separately could not induce cytolysis. Contact stimulation, even for a brief period, sufficed for cytolytic activity, and was enhanced by culture for 48-72 h. Through in vivo studies, the suppression of tumor growth and a prolongation of the survival time were observed in tumorbearing mice injected with spleen cells activated by beads immobilizing LPS fromE.coli, and in mice injected with LAK cells. The effect of the activated spleen cells was stronger than that of the LAK cells. In rats bearing metastatic tumors, spleen cells activated by beads immobilizing LPS fromS.minnesota suppressed lung metastases more strongly than did LAK cells. These findings indicate that LPS immobilized by beads induced killer cells more strongly than interleukin-2. Ex vivo immunomodulation with LPS-immobilizing beads can be applied usefully as an anticancer treatment. Springer-Verlag, 1992 Lipopolysaccharide (LPS) nationallicence Immobilizing material nationallicence Immunomodulation nationallicence Spleen cells nationallicence Abe Hajime First Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa, 520-21, Otsu, Shiga, Japan aut Tani Tohru First Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa, 520-21, Otsu, Shiga, Japan aut Shibata Junsuke First Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa, 520-21, Otsu, Shiga, Japan aut Kodama Masashi First Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa, 520-21, Otsu, Shiga, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 35/1(1992-01-01), 39-45 0340-7004 35:1<39 1992 35 262 https://doi.org/10.1007/BF01741053 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741053 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Abe Hajime First Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa, 520-21, Otsu, Shiga, Japan aut NATIONALLICENCE 700 1- Tani Tohru First Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa, 520-21, Otsu, Shiga, Japan aut NATIONALLICENCE 700 1- Shibata Junsuke First Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa, 520-21, Otsu, Shiga, Japan aut NATIONALLICENCE 700 1- Kodama Masashi First Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa, 520-21, Otsu, Shiga, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/1(1992-01-01), 39-45 0340-7004 35:1<39 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer